Ferenc G. Rick

2.3k total citations
63 papers, 1.9k citations indexed

About

Ferenc G. Rick is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Molecular Biology. According to data from OpenAlex, Ferenc G. Rick has authored 63 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Endocrinology, Diabetes and Metabolism, 27 papers in Oncology and 23 papers in Molecular Biology. Recurrent topics in Ferenc G. Rick's work include Growth Hormone and Insulin-like Growth Factors (26 papers), Cancer-related Molecular Pathways (14 papers) and Prostate Cancer Treatment and Research (10 papers). Ferenc G. Rick is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (26 papers), Cancer-related Molecular Pathways (14 papers) and Prostate Cancer Treatment and Research (10 papers). Ferenc G. Rick collaborates with scholars based in United States, Germany and Hungary. Ferenc G. Rick's co-authors include Andrew V. Schally, Norman L. Block, Luca Szalontay, Márta Zarándi, Irving Vidaurre, Gábor Halmos, Petra Popovics, Roberto Pérez‐Castañeda, Florian Hohla and Stefan Buchholz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Oncogene.

In The Last Decade

Ferenc G. Rick

63 papers receiving 1.9k citations

Peers

Ferenc G. Rick
Natalie Sampson Austria
Carla Costa Portugal
Fraser M. Rogerson Australia
Shigekazu Sasaki Japan
Paola Concolino Italy
Kelly A. Chiles United States
José Manuel González‐Sancho Spain
Xiaowei Zheng Sweden
Qi Cao China
Chiung‐Kuei Huang United States
Natalie Sampson Austria
Ferenc G. Rick
Citations per year, relative to Ferenc G. Rick Ferenc G. Rick (= 1×) peers Natalie Sampson

Countries citing papers authored by Ferenc G. Rick

Since Specialization
Citations

This map shows the geographic impact of Ferenc G. Rick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferenc G. Rick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferenc G. Rick more than expected).

Fields of papers citing papers by Ferenc G. Rick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ferenc G. Rick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferenc G. Rick. The network helps show where Ferenc G. Rick may publish in the future.

Co-authorship network of co-authors of Ferenc G. Rick

This figure shows the co-authorship network connecting the top 25 collaborators of Ferenc G. Rick. A scholar is included among the top collaborators of Ferenc G. Rick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ferenc G. Rick. Ferenc G. Rick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Crawford, E. David, Andrew V. Schally, Jehonathan H. Pinthus, et al.. (2017). The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urologic Oncology Seminars and Original Investigations. 35(5). 183–191. 72 indexed citations
2.
Zarándi, Márta, Renzhi Cai, Magdolna Kovács, et al.. (2017). Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth. Peptides. 89. 60–70. 52 indexed citations
3.
Romero, Maritza J., Rudolf Lucas, Huijuan Dou, et al.. (2016). Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes. Proceedings of the National Academy of Sciences. 113(7). 1895–1900. 14 indexed citations
4.
Crawford, E. David, Kyle O. Rove, Andrew V. Schally, et al.. (2014). The Role of the FSH System in the Development and Progression of Prostate Cancer. 10(6). 15 indexed citations
5.
Czikora, István, Supriya Sridhar, Boris Gorshkov, et al.. (2014). Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction. Frontiers in Physiology. 5. 259–259. 22 indexed citations
6.
Seitz, Stephan, Stefan Buchholz, Andrew V. Schally, et al.. (2014). Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer. 14(1). 847–847. 47 indexed citations
7.
Rick, Ferenc G. & Andrew V. Schally. (2014). Bench-to-bedside development of agonists and antagonists of luteinizing hormone–releasing hormone for treatment of advanced prostate cancer. Urologic Oncology Seminars and Original Investigations. 33(6). 270–274. 25 indexed citations
8.
Rick, Ferenc G., et al.. (2013). An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. OncoTargets and Therapy. 6. 391–391. 34 indexed citations
9.
Seitz, S., Ferenc G. Rick, Andrew V. Schally, et al.. (2013). Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. Oncology Reports. 30(1). 413–418. 26 indexed citations
10.
Pérez‐Castañeda, Roberto, et al.. (2012). Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. Oncotarget. 3(9). 988–997. 43 indexed citations
11.
Rick, Ferenc G., Stefan Buchholz, Andrew V. Schally, et al.. (2012). Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle. 11(13). 2518–2525. 23 indexed citations
12.
Rick, Ferenc G., Seyed Hassan Saadat, Luca Szalontay, et al.. (2012). Hormonal manipulation of benign prostatic hyperplasia. Current Opinion in Urology. 23(1). 17–24. 16 indexed citations
13.
14.
15.
Kovács, Magdolna, Andrew V. Schally, Florian Hohla, et al.. (2010). A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides. 31(10). 1839–1846. 22 indexed citations
16.
Hohla, Florian, Stefan Buchholz, Andrew V. Schally, et al.. (2010). Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Letters. 294(1). 35–42. 24 indexed citations
17.
Rick, Ferenc G., Andrew V. Schally, Norman L. Block, et al.. (2010). LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. The Prostate. 71(7). 736–747. 71 indexed citations
18.
Treszl, Andrea, Andrew V. Schally, Stephan Seitz, et al.. (2009). Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162. Peptides. 30(9). 1643–1650. 13 indexed citations
19.
Hohla, Florian, Stefan Buchholz, Andrew V. Schally, et al.. (2009). GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle. 8(19). 3149–3156. 35 indexed citations
20.
Seitz, Stephan, Andrew V. Schally, Andrea Treszl, et al.. (2009). Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition. Anti-Cancer Drugs. 20(7). 553–558. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Natalie Sampson Breakdown of academic impact, for papers by Carla Costa Breakdown of academic impact, for papers by Fraser M. Rogerson Breakdown of academic impact, for papers by Shigekazu Sasaki Breakdown of academic impact, for papers by Paola Concolino Breakdown of academic impact, for papers by Kelly A. Chiles Breakdown of academic impact, for papers by José Manuel González‐Sancho Breakdown of academic impact, for papers by Xiaowei Zheng Breakdown of academic impact, for papers by Qi Cao Breakdown of academic impact, for papers by Chiung‐Kuei Huang
Rankless by CCL
2026